Amgen Beats Earnings Expectations and Expands into Obesity Drug Space

) reported third-quarter earnings that beat expectations and raised its full-year revenue guidance. The company recently completed its acquisition of Horizon Therapeutics, which brings its drug Tepezza to Amgen. Amgen is also looking to move into the obesity drug space which has garnered much attention from Wall Street.

Shakedown or smart business? Quebec restaurants balk at hefty penalty for using competitor's payment machines Warren Buffett's Japan trade felt like a gift from God, Charlie Munger says: 'It was awfully easy money' TSX energy stocks such as Suncor Energy should be part of your equity portfolio if you are bullish on oil prices in 2023. The post Oil Prices Are Rising: Here Are the Stocks That Will Benefit the Most appeared first on The Motley Fool Canada.Rated lowest margin fees by StockBrokers.com. Borrow against your securities at low cost. Rates subject to change. Your capital is at risk.

الإمارات العربية المتحدة أحدث الأخبار, الإمارات العربية المتحدة عناوين

Similar News:يمكنك أيضًا قراءة قصص إخبارية مشابهة لهذه التي قمنا بجمعها من مصادر إخبارية أخرى.

Amgen Reports 5% Rise in Q3 Product Sales After Horizon Therapeutics AcquisitionAmgen announces a 5% increase in third-quarter product sales, driven by double-digit volume growth but offset by lower prices. The company also raises its post-acquisition sales forecast and adjusted earnings outlook for 2023.
مصدر: SaltWire Network - 🏆 45. / 63 اقرأ أكثر »